SUE GAIL ECKHARDT, MD
Osteopathic Medicine at 16 Ave, Denver, CO
License number
Colorado 38160
Category
Osteopathic Medicine
Type
Medical Oncology
Address
Address
12605 E 16Th Ave, Denver, CO 80045
Phone
(720) 848-0000
(303) 493-7000
(303) 493-7000
Personal information
See more information about SUE GAIL ECKHARDT at radaris.comName
Address
Phone
1372 Rawhide Cir, Elizabeth, CO 80107
10930 Powers Ave, Littleton, CO 80127
2462 Baldy Ln, Evergreen, CO 80439
Professional information
See more information about SUE GAIL ECKHARDT at trustoria.com
Sue Gail Eckhardt, Aurora CO
Sue Gail Eckhardt, Aurora CO
Specialties:
Internal Medicine, Medical Oncology, Hematology & Oncology
Work:
University of Colorado Hospital
1665 Aurora Ct, Aurora, CO 80045
1665 Aurora Ct, Aurora, CO 80045
Education:
The University of Texas at Galveston (1985)
Sue Gail Eckhardt, Aurora CO
Sue Gail Eckhardt, Aurora CO
Specialties:
Oncologist
Address:
12605 E 16Th Ave, Aurora, CO 80045
Biological Markers Predictive Of Anti-Cancer Response To Insulin-Like Growth Factor-1 Receptor Kinase Inhibitors
Biological Markers Predictive Of Anti-Cancer Response To Insulin-Like Growth Factor-1 Receptor Kinase Inhibitors
US Patent:
2010024, Sep 23, 2010
Filed:
Oct 20, 2009
Appl. No.:
12/582013
Inventors:
Sue Gail ECKHARDT - Evergreen CO, US
Todd Michael PITTS - Thornton CO, US
Aik Choon TAN - Englewood CO, US
Todd Michael PITTS - Thornton CO, US
Aik Choon TAN - Englewood CO, US
Assignee:
THE REGENTS OF THE UNIVERSITY OF COLORADO - Denver CO
International Classification:
A61K 31/4985, C12Q 1/68, C12Q 1/48, C12Q 1/32, C12Q 1/42, C12Q 1/00
US Classification:
514249, 435 6, 435 15, 435 26, 435 21, 435 4
Abstract:
The present invention provides diagnostic methods for predicting the effectiveness of treatment of a cancer patient with an IGF-1R kinase inhibitor. Methods are provided for predicting the sensitivity of tumor cell growth to inhibition by an IGF-1R kinase inhibitor, comprising assessing whether the tumor cell expresses certain sensitivity or resistance biomarkers, or genomic classifiers. Improved methods for treating cancer patients with IGF-1R kinase inhibitors that incorporate this methodology are also provided.
Biological Markers Predictive Of Anti-Cancer Response To Insulin-Like Growth Factor-1 Receptor Kinase Inhibitors
Biological Markers Predictive Of Anti-Cancer Response To Insulin-Like Growth Factor-1 Receptor Kinase Inhibitors
US Patent:
2012020, Aug 9, 2012
Filed:
Apr 23, 2012
Appl. No.:
13/453719
Inventors:
Sue Gail ECKHARDT - Evergreen CO, US
Todd Michael PITTS - Thornton CO, US
Aik Choon TAN - Englewood CO, US
Todd Michael PITTS - Thornton CO, US
Aik Choon TAN - Englewood CO, US
Assignee:
THE REGENTS OF THE UNIVERSITY OF COLORADO - Denver CO
International Classification:
A61K 39/395, A61P 35/00, G01N 21/64
US Classification:
4241581, 435 611
Abstract:
The present invention provides diagnostic methods for predicting the effectiveness of treatment of a cancer patient with an IGF-1R kinase inhibitor. Methods are provided for predicting the sensitivity of tumor cell growth to inhibition by an IGF-1R kinase inhibitor, comprising assessing whether the tumor cell expresses certain sensitivity or resistance biomarkers, or genomic classifiers. Improved methods for treating cancer patients with IGF-1R kinase inhibitors that incorporate this methodology are also provided.